GD
ALNY icon

Grandfield & Dodd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Grandfield & Dodd’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Buy
3,204
+123
+4% +$37.1K 0.05% 115
2026
Q1 		$1.02M Sell
3,081
-48
-2% -$16.3K 0.06% 108
2025
Q4 		$1.24M Buy
3,129
+9
+0.3% +$3.98K 0.07% 105
2025
Q3 		$1.42M Buy
3,120
+68
+2% +$27.7K 0.08% 100
2025
Q2 		$995K Buy
3,052
+20
+0.7% +$5.53K 0.06% 109
2025
Q1 		$819K Buy
3,032
+659
+28% +$169K 0.05% 111
2024
Q4 		$558K Buy
2,373
+1,149
+94% +$302K 0.03% 135
2024
Q3 		$337K Buy
+1,224
New +$319K 0.02% 164

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grandfield & Dodd's ALNY Position: Q2 2026 in Review

Grandfield & Dodd increased its Alnylam Pharmaceuticals (ALNY) stake by 4% in Q2 2026, buying an estimated $37.1K and bringing the position to 3,204 shares worth $965K. The position accounts for 0.05% of the portfolio, ranked #115.

Grandfield & Dodd first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.42M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Grandfield & Dodd held 3,204 shares of Alnylam Pharmaceuticals worth $965K as of Q2 2026.
  • Grandfield & Dodd bought 123 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $37.1K.
  • Alnylam Pharmaceuticals made up 0.05% of Grandfield & Dodd's portfolio in Q2 2026, its #115 holding.
  • Grandfield & Dodd first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Grandfield & Dodd's Alnylam Pharmaceuticals position peaked at $1.42M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.